GlassScriptPhysician profile
Robert R Revers
NPI 1598762718
$6,137.33
in general payments reported to CMS, 2019-2025
40 companies · $424 in 2025
The $424 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $159 · 2021: $395 · 2022: $1,414 · 2023: $1,846 · 2024: $1,045 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,055.12 | 2019-2025 | |
| Novo Nordisk INC | $789.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $772.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $756.41 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbott Laboratories | $494.58 | 2020-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $467.41 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $226.14 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $192.81 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $148.41 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $132.10 | 2019-2023 | |
| Dexcom, INC. | $106.24 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $105.60 | 2019-2025 | |
| Glaxosmithkline, LLC. | $90.43 | 2019-2023 | Arexvy, Shingrix |
| Radius Health, INC. | $79.01 | 2019-2023 | Tymlos |
| Biohaven Pharmaceutical Holding Company LTD. | $69.96 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Revers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.